Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Q32 Bio on the deal. Q32 Bio announced its collaboration and option agreement with Horizon Therapeutics Ireland DAC under which both companies will collaborate...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Scholar Rock Holding Corporation on the deal. Scholar Rock Holding Corporation announced the completion of its registered direct offering of 16,326,530 shares of common...
You must be a Standard 1 Year member to access this content.
Arnold & Porter advised Sanofi on the deal while Goodwin Procter represented Seagen. Sanofi announced its exclusive collaboration with Nasdaq-listed biotech Seagen Inc. to design, develop and...
You must be a Standard 1 Year member to access this content.
Cravath and Saraf and Partners represented Viatris in the transaction while Shardul Amarchand Mangaldas & Co and Goodwin Procter advised Biocon Biologics. Viatris Inc. reached a...
You must be a Standard 1 Year member to access this content.
Hogan Lovells has advised EyePoint Pharmaceuticals, Inc. on the deal. Cowen and Guggenheim Securities acted as joint book-running managers for the offering. Among other uses, this...
You must be a Standard 1 Year member to access this content.
